Browsing NHH Brage by Author "Dalen, Dag Morten"
Now showing items 1-10 of 10
-
Competing with precision: incentives for developing predictive biomarker tests
Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;06/2022, Working paper, 2022-03)We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework ... -
Competing with precision: incentives for developing predictive biomarker tests
Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2023)We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose, we develop a two-dimensional spatial framework ... -
Diffusion of pharmaceuticals : cross-country evidence of anti-TNF drugs
Brekke, Kurt Richard; Dalen, Dag Morten; Holmås, Tor Helge (Discussion paper;7/2013, Working paper, 2013-03)This paper studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information on ... -
Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs
Brekke, Kurt; Dalen, Dag Morten; Holmås, Tor Helge (Journal article; Peer reviewed, 2014)This article studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information ... -
Paying for pharmaceuticals: uniform pricing versus two-part tariffs
Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2022)Two-part pricing (the Netflix model) has recently been proposed instead of uniform pricing for pharmaceuticals. Under two-part pricing the health plan pays a fixed fee for access to a drug at unit prices equal to marginal ... -
The Price of Cost-effectiveness Thresholds
Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;04/2023, Working paper, 2023)Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform decisions about access and reimbursement. We study how CE thresholds imposed by a health plan for granting reimbursement ... -
Regulering og internasjonal regelverkskonkurranse i finansnæringen
Dalen, Dag Morten (Rapport, Research report, 2000-04)Med Norges tilslutning til EØS-avtalen og gjennomføringen av EUs indre finansmarked er norske finansinstitusjoner i større grad enn før utsatt for konkurranse fra utenlandske aktører. Utenlandske finansforetak kan etablere ... -
Strategic regulation of a multi-national banking industry
Dalen, Dag Morten; Olsen, Trond E. (Discussion paper, Working paper, 2002-12)This paper focuses on the consequences of cross-border banking and entry of multi-national bank (MNB) subsidiaries for banking supervision and regulation. When a MNB expands internationally with subsidiaries, the MNB ... -
Taking the competitor’s pill: when combination therapies enter pharmaceutical markets
Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (DP SAM;19/2023, Working paper, 2023-11-22)We study the competitive effects of combination therapies in pharmaceutical markets, which crucially hinge on the additional therapeutic value of combinatory use of drugs and the therapeutic substitutability with the most ... -
The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets
Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2023)